Superseded public profile

Not FDA-approved↗Safety records↗

Superseded · version 3: TB-500↗↗

Related names recorded in this version: N-terminal acetylated 17-23 fragment of thymosin beta-4↗↗

A thymosin beta-4 fragment represented in FDA identity and pharmacy-compounding review records.↗↗

This is preserved historical wording.
It is no longer the current profile. Read the canonical profile and its correction notice.
Correction · September 15, 2026

We narrowed the status wording to what the dated FDA briefing establishes. A briefing prepared for an advisory process does not establish the current absence of a later final decision. Related substance identities remain distinct. 2

What this version reported

FDA's July 2026 briefing evaluates TB-500-related bulk drug substances for pharmacy compounding. The briefing is an advisory-process assessment, not a final regulatory determination.↗

Organizations named in cited records:

Sources for this version

  1. 1
    TB-500 substance identity record ↗

    FDA Global Substance Registration System · Official source · Source checked July 29, 2026

  2. 2
    FDA briefing document for TB-500 ↗

    U.S. Food and Drug Administration · Official source · Source checked November 14, 2026

  3. 3
    July 23-24, 2026 Pharmacy Compounding Advisory Committee meeting ↗

    U.S. Food and Drug Administration · Official source · Source checked November 14, 2026